<SEC-DOCUMENT>0001104659-21-096999.txt : 20210728
<SEC-HEADER>0001104659-21-096999.hdr.sgml : 20210728
<ACCEPTANCE-DATETIME>20210728164137
ACCESSION NUMBER:		0001104659-21-096999
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210728
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210728
DATE AS OF CHANGE:		20210728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		211123093

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2123578d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
<B>WASHINGTON, D. C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
July 28, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PRECIPIO, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B><I>(Exact Name of Registrant as Specified in Its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>Delaware<BR>
</B><I>(State of Incorporation)</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>001-36439<BR>
</B><I>(Commission File Number)</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center; width: 32%"><FONT STYLE="font-size: 10pt"><B>91-1789357<BR>
</B><I>(I.R.S. Employer Identification No.)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4 Science Park, New Haven, CT 06511</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive offices) (Zip
Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(203) 787-7888</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Registrant's telephone number, including area
code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable<BR>
</B><I>(Former name, former address and former fiscal year, if changed since last report date)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 34%; padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding: 1.5pt; font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">Title of each class</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">Ticker symbol(s)</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">Name of each exchange on which registered</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">Common Stock, $0.01 par value per share</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">PRPO</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; font-size: 10pt; text-align: center">The Nasdaq Stock Market LLC</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 2.02</B></TD><TD><B>Results of Operations and financial Conditions</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On July 28, 2021, the
Company issued a press release announcing its preliminary, unaudited Q2-2021 revenues. The press release is furnished as Exhibit 99.1
and incorporated herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Current Report on Form 8-K, including Exhibit
99.1 attached hereto, is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that Section, nor shall
it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any
filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof,
regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission
as to the materiality of any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tm2123578d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="text-align: justify"><A HREF="tm2123578d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Precipio Inc Press Release July 28, 2021</A></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>PRECIPIO, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%">s/ Ilan Danieli </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Ilan Danieli</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&#9;July 28, 2021 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2123578d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="image_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Precipio Announces Preliminary Unaudited Q2-2021
Revenues of $2.3M </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>Increase of 65%
YoY, and 29% from Q1-2021 due to strong Pathology Growth and HemeScreen</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEW HAVEN, CT, (July 28, 2021) </B>&ndash;
Specialty diagnostics Company <FONT STYLE="color: Blue"><U>Precipio, Inc.</U></FONT><FONT STYLE="color: #165B8E">&nbsp; </FONT><FONT STYLE="color: Blue"><U>(NASDAQ:
PRPO)</U></FONT>, announces preliminary unaudited revenues for Q2-2021 demonstrating continued substantial YoY and quarterly growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The two key factors driving the increase in revenue
are the company&rsquo;s continued addition of new business in the pathology services division, as well as revenues generated by our HemeScreen
POL program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Pathology services </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pathology services division continues to perform
well as we experience this significant growth. With quarterly case volume up 60% YoY, our laboratory team is meeting this challenge with
great success, ensuring that the accuracy, quality, and service levels expected by our customers are met. As case volume and associated
revenue continue to grow, this division continues to make strides towards achieving operational breakeven.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD STYLE="text-align: justify"><B>HemeScreen POL </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to onboard new Physician Oncology
Lab (&ldquo;POL&rdquo;) customers as we expand the technology to new cancer diagnostic panels. As we build this recurring B2B business,
we anticipate not only continued revenue growth, but profits that should lead to material reductions in our cash-burn. Customers who sign
up for the HemeScreen POL program enter into a 4-year commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we expand our panel offering, each POL customer
can generate increasing recurring revenues for Precipio. Simply stated, each new customer contract adds another building block to a solid
and growing customer base, and each new panel adds another building block that should expand revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The HemeScreen technology and resulting diagnostic
improvements in both accuracy and reduced reporting turn-around-time are impactful both to patient care, and to the practice&rsquo;s finances.
We are encouraged by the magnitude of interest in the program from both small groups (upwards of 3 physicians) as well as significantly
larger practices. Management anticipates that both the number of new practices, and revenue generated from them should continue to accelerate
throughout 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I&rsquo;m proud of our team that has continued
to work diligently to grow the Pathology business. Furthermore, Taking a technology developed at Precipio and creating a proprietary and
protected product with meaningful clinical and economic benefit to our customers, is an example of our development capabilities&rdquo;,
said Ilan Danieli, Precipio&rsquo;s CEO. &ldquo;HemeScreen has an opportunity to be a world-wide technology as it continues to prove itself
as a game-changing technology.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Precipio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Precipio has built a platform designed to eradicate
the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering
quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide.
Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as
the Yale School of Medicine, Harvard&rsquo;s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new
standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit <FONT STYLE="color: blue"><U>www.precipiodx.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please follow us on Twitter <FONT STYLE="color: blue"><U>@PrecipioDx</U></FONT>
and on <FONT STYLE="color: blue"><U>Facebook</U></FONT>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19)
pandemic, and the related responses of the government, consumers, and the Company, on our business, financial condition and results of
operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions
and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings,
earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking
statements based on management&rsquo;s estimates, beliefs, assumptions and projections. Words such as &ldquo;could,&rdquo; &ldquo;may,&rdquo;
 &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;will,&rdquo; &ldquo;targets,&rdquo; &ldquo;goals,&rdquo; &ldquo;projects,&rdquo;
 &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo;
and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic
and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions,
subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect
performance and cause results to differ materially from management&rsquo;s expectations, or could affect the Company&rsquo;s ability to
achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the Company&rsquo;s business, operations
and employees and the other factors that are described in the sections entitled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis&rdquo; in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated from
time to time in the Company&rsquo;s Securities and Exchange Commission filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s forward-looking statements
in this press release are based on management&rsquo;s current views, beliefs, assumptions and expectations regarding future events and
speak only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by the federal securities laws.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC"><FONT STYLE="color: Blue"><B><U>investors@precipiodx.com</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">+1-203-787-7888
Ext. 523</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( 6\# 2(  A$! Q$!_\0
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M1 M_^N\O_H5=Y3E*S:LA):'GGV/XJ?\ 03T;_OW_ /8T?8_BI_T$]&_[]_\
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M,@UR^J> =(OMSVX:SE/.8ON_]\GC\L5RRPDHN\&<$\!.#YJ3-/0M=M-=LA/
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MG>I?6/\ ]#%=H*YGQ]I%[KO@V_T^PC62YD"%$9@N<,">3]*\B.Z.I[&MH/\
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#S__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
